FDA grants fast track status for Edge Therapeutics’ EG-1962 to treat subarachnoid hemorrhage
"We are very pleased that FDA has granted Fast Track designation for EG-1962 for the treatment of SAH," said Brian A. Leuthner, Edge’s Chief Executive Officer. "The FDA
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.